{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:16Z","timestamp":1793157436088,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chemoimmunotherapy is recommended for patients with non\u2013small cell lung cancer (NSCLC) with low PD-L1 expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICI) to chemotherapy, we conducted a retrospective study at 19 institutions in Japan. We analyzed 851 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% to 49% who received chemoimmunotherapy (n = 504) or chemotherapy (n = 347) between March 2017 and June 2022. After adjustment by propensity score matching, the median overall survival (OS) was 22.3 months in the chemoimmunotherapy group and 17.0 months in the chemotherapy-alone group (P = 0.01). Multivariate analysis showed that among 12 clinical factors, liver metastases (P = 0.001) and history of antibiotic use (P = 0.02) were independently associated with shorter OS in the chemoimmunotherapy group. Patients with liver metastases (OS, P = 0.4; progression-free survival, P = 0.06) or history of antimicrobial use (OS, P = 0.24; progression-free survival, P = 0.09) did not benefit from the addition of ICI to chemotherapy. Patients with a history of antimicrobial use experienced more severe pneumonitis with chemoimmunotherapy than all patients (P = 0.04). This cohort study showed that liver metastases and prior antimicrobial therapy are the most important clinical factors that attenuate the efficacy of chemoimmunotherapy in patients with low PD-L1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study shows that liver metastases and prior antibiotic use are key factors for chemoimmunotherapy in advanced NSCLC cases with low PD-L1 expression. They reduce the benefit of adding ICIs to chemotherapy, underscoring the need for new strategies to improve ICI efficacy in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0157","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T11:17:12Z","timestamp":1752146232000},"page":"1203-1214","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1\u2013Expressing Non\u2013Small Cell Lung Cancer"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-2280","authenticated-orcid":false,"given":"Tae","family":"Hata","sequence":"first","affiliation":[{"name":"1Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"1Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-8567","authenticated-orcid":false,"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[{"name":"2Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2558-932X","authenticated-orcid":false,"given":"Akihiko","family":"Amano","sequence":"additional","affiliation":[{"name":"3Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5059-4654","authenticated-orcid":false,"given":"Yoshiki","family":"Negi","sequence":"additional","affiliation":[{"name":"4Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"5Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-5946","authenticated-orcid":false,"given":"Naoki","family":"Furuya","sequence":"additional","affiliation":[{"name":"6Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1500-5215","authenticated-orcid":false,"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[{"name":"7Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-3425","authenticated-orcid":false,"given":"Tatsuki","family":"Ikoma","sequence":"additional","affiliation":[{"name":"8Department of Thoracic Oncology, Kansai Medical University, Hirakata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-4227","authenticated-orcid":false,"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[{"name":"9Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4466","authenticated-orcid":false,"given":"Keiko","family":"Tanimura","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Fukuchiyama City Hospital, Fukuchiyama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-8344","authenticated-orcid":false,"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"11Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-2110","authenticated-orcid":false,"given":"Akihiro","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"12Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-4401","authenticated-orcid":false,"given":"Tomoya","family":"Fukui","sequence":"additional","affiliation":[{"name":"13Department of Respiratory Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4295-5046","authenticated-orcid":false,"given":"Daiki","family":"Murata","sequence":"additional","affiliation":[{"name":"14Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"15Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-0770","authenticated-orcid":false,"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[{"name":"16Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-5027","authenticated-orcid":false,"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"17Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-2257","authenticated-orcid":false,"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[{"name":"18Department of Respiratory Medicine, Saiseikai Suita Hospital, Suita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-844X","authenticated-orcid":false,"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[{"name":"19Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-2260","authenticated-orcid":false,"given":"Hayato","family":"Kawachi","sequence":"additional","affiliation":[{"name":"1Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-4021","authenticated-orcid":false,"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"4Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-8960","authenticated-orcid":false,"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"1Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025072301100317200_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2025072301100317200_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025072301100317200_bib3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2025072301100317200_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025072301100317200_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025072301100317200_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025072301100317200_bib7","doi-asserted-by":"crossref","first-page":"114296","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025072301100317200_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"2025072301100317200_bib9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025072301100317200_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"2025072301100317200_bib11","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2025072301100317200_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"2025072301100317200_bib13","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.3390\/cancers15204988","article-title":"First-line chemoimmunotherapy versus sequential platinum-based chemotherapy followed by immunotherapy in patients with non-small cell lung cancer with \u226449% programmed death-ligand 1 expression: a real-world multicenter retrospective study","volume":"15","author":"Tanimura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025072301100317200_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","article-title":"Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer","volume":"10","author":"Tsukita","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025072301100317200_bib15","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025072301100317200_bib16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","article-title":"Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC","volume":"16","author":"Shirasawa","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025072301100317200_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2022.4933","article-title":"Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC","volume":"9","author":"Rakaee","year":"2023","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"2025072301100317200_bib18","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1073\/pnas.1000087107","article-title":"Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation","volume":"108","author":"Dethlefsen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025072301100317200_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"2025072301100317200_bib20","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann Oncol"},{"key":"2025072301100317200_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2025072301100317200_bib22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025072301100317200_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2025072301100317200_bib24","doi-asserted-by":"crossref","first-page":"893716","DOI":"10.3389\/fonc.2022.893716","article-title":"Research progress on the microenvironment and immunotherapy of advanced non-small cell lung cancer with liver metastases","volume":"12","author":"Fang","year":"2022","journal-title":"Front Oncol"},{"key":"2025072301100317200_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025072301100317200_bib26","doi-asserted-by":"crossref","first-page":"102893","DOI":"10.1016\/j.critrevonc.2020.102893","article-title":"The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer","volume":"147","author":"Qin","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025072301100317200_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21037\/tlcr.2019.10.23","article-title":"The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer","volume":"8","author":"Katayama","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2025072301100317200_bib28","doi-asserted-by":"crossref","first-page":"e2322915","DOI":"10.1001\/jamanetworkopen.2023.22915","article-title":"Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer","volume":"6","author":"Kawachi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025072301100317200_bib29","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","article-title":"Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer","volume":"8","author":"Tomita","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2025072301100317200_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"2025072301100317200_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/14737140.2015.992785","article-title":"Cancer and the microbiome: potential applications as new tumor biomarker","volume":"15","author":"Shahanavaj","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025072301100317200_bib32","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/jac\/dkl420","article-title":"Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes","volume":"58","author":"L\u00f6fmark","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2025072301100317200_bib33","first-page":"1106","article-title":"Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature","volume":"14","author":"Martins Lopes","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"2025072301100317200_bib34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"key":"2025072301100317200_bib35","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/1759-7714.13573","article-title":"Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP)","volume":"11","author":"Ruiz-Pati\u00f1o","year":"2020","journal-title":"Thorac Cancer"},{"key":"2025072301100317200_bib36","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025072301100317200_bib37","doi-asserted-by":"crossref","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025072301100317200_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ijms22010042","article-title":"Infections and immunotherapy in lung cancer: a bad relationship?","volume":"22","author":"Belluomini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025072301100317200_bib39","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.3390\/curroncol30090614","article-title":"The impact of oral antibiotics prior to cancer diagnosis on overall patient survival: findings from an English population-based cohort study","volume":"30","author":"Domzaridou","year":"2023","journal-title":"Curr Oncol"},{"key":"2025072301100317200_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cllc.2022.09.005","article-title":"Antibiotic prescriptions in lung cancer and melanoma populations: differences with potential clinical implications in the immunotherapy era","volume":"24","author":"Gonugunta","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2025072301100317200_bib41","doi-asserted-by":"crossref","first-page":"e2214046","DOI":"10.1001\/jamanetworkopen.2022.14046","article-title":"Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non-small cell lung cancer","volume":"5","author":"Popat","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025072301100317200_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12957-020-1792-4","article-title":"Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis","volume":"18","author":"Mo","year":"2020","journal-title":"World J Surg Oncol"},{"key":"2025072301100317200_bib43","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1759-7714.13852","article-title":"Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study","volume":"12","author":"Cortellini","year":"2021","journal-title":"Thorac Cancer"},{"key":"2025072301100317200_bib44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.21037\/tlcr-24-142","article-title":"Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review","volume":"13","author":"Kaira","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"2025072301100317200_bib45","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025072301100317200_bib46","doi-asserted-by":"crossref","first-page":"108447","DOI":"10.1016\/j.lungcan.2025.108447","article-title":"Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: the SPIRAL-STEP study","volume":"201","author":"Morimoto","year":"2025","journal-title":"Lung Cancer"},{"key":"2025072301100317200_bib47","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/1759-7714.14836","article-title":"Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: a multicenter retrospective study","volume":"14","author":"Hata","year":"2023","journal-title":"Thorac Cancer"},{"key":"2025072301100317200_bib48","doi-asserted-by":"crossref","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0157\/3629967\/crc-25-0157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1203\/3633236\/crc-25-0157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1203\/3633236\/crc-25-0157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T05:10:10Z","timestamp":1753247410000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/7\/1203\/763746\/Chemoimmunotherapy-Outcomes-and-Prognostic-Factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0157","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29623979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623913","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623967","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624060","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624051","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624054","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624042","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624045","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624066","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624036","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624069","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624057","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29624006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29623985","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7943078","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}